Type 2 Diabetes Clinical Trial
— GLP-1inT2DOfficial title:
Effects of Meal Timing on Postprandial Glucose, Insulin and GLP-1 Responses After Breakfast Lunch and Dinner in Patients With Type 2 Diabetes
Enhanced insulin and GLP-1 postprandial response after morning meal versus evening meal,
might be underlying explanation of the beneficial effect of eating breakfast with reduced
dinner vs skipping breakfast on glycemic control and HbA1c in T2D patients.
To test this hypothesis and clarify whether glucose, insulin and GLP-1 postprandial
responses are different in the morning vs. in the afternoon, the investigators will compare
in T2D subjects in random order and in two separate days: the glucose, insulin and GLP-1
postprandial responses after breakfast, lunch and dinner with 2 isocaloric meal plans or
test diets, that differ in meal timing distribution The investigators hypothesize that GLP-1
and insulin response after high calorie breakfast will be higher in comparison to GLP-1 and
insulin response after identical meal at evening
| Status | Recruiting |
| Enrollment | 30 |
| Est. completion date | January 2014 |
| Est. primary completion date | December 2013 |
| Accepts healthy volunteers | No |
| Gender | Both |
| Age group | 30 Years to 70 Years |
| Eligibility |
Inclusion Criteria: 1. Type 2 diabetes patients 2. HbA1C > 7% 3. Duration of diabetes: 0.5 to 10 years 4. Subjects = 30 and =70 years of age 5. BMI: 22 to 35 kg/m2 6. Diet controlled diabetic. Only treatment with metformin will be allowed 7. Normal liver and kidney function 8. Normal thyroid function 9. Acceptable health beside diabetes based on interview, medical history, physical examination, and laboratory tests 10. Stable physical activity pattern during the three months immediately preceding study 11. Usually wakes up between 06:00 and 07:00 and goes to sleep between 22:00 and 24:00. 12. No shift work within 5 years of the study 13. Did not cross time zones within 1 month of the study 14. Read and understood the informed consent form and signed it voluntarily Exclusion Criteria: 1. Type 1 diabetes 2. Clinically significant pulmonary, cardiac, renal, hepatic, neurologic, psychiatric, infectious, malignant disease 3. Abnormal liver function tests defined as an increase by a factor of at least 2 above the upper normal limit of alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) 4. Pregnancy or lactation 5. Illicit drug abuse or alcoholism 6. Treatment with antidiabetic drugs, insulin or GLP-1 analogs 7. Subjects taking anoretic drugs during the month immediately prior to study 8. Subjects on steroid treatment 9. Those with eating disorders 10. Subjects after bariatric surgery, will be excluded |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment
| Country | Name | City | State |
|---|---|---|---|
| Israel | Diabetes Unit E. Wolfson Medical center | Holon | Tel Aviv |
| Lead Sponsor | Collaborator |
|---|---|
| Tel Aviv University | Wolfson Medical Center |
Israel,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Other | Postprandial Insulin plasma levels, after breakfast,lunch and dinner meal test | All Type 2 diabetic participants will be randomly assigned to one of 2 isocaloric diet sequences that will differ in the meal timing distribution. The diets will be tested in two separate occasions during a curse of a single day (test day) in which postprandial plasma Insulin levels during 3 hours after breakfast, lunch and dinner meal challenge will be measured | During 3 hours, after breakfast,lunch and dinner meal test | No |
| Primary | Postprandial GLP-1 plasma levels, after breakfast,lunch and dinner meal test | All Type 2 diabetic participants will be randomly assigned to one of 2 isocaloric diet sequences that will differ in the meal timing distribution. The diets will be tested in two separate occasions during a curse of a single day (test day) in which postprandial plasma GLP-1 levels during 3 hours after breakfast, lunch and dinner meal challenge will be measured | During 3 hours after breakfast, lunch and dinner meal challange | No |
| Secondary | Postprandial Plasma Glucose levels after breakfast, lunch and dinner meal challenge | All Type 2 diabetic participants will be randomly assigned to one of 2 isocaloric diet sequences that will differ in the meal timing distribution. The diets will be tested in two separate occasions during a curse of a single day (test day) in which postprandial plasma Glucose levels during 3 hours after breakfast, lunch and dinner meal challenge will be measured | Postprandial Plasma Glucose levels during 3 hours after breakfast, lunch and dinner meal challenge | No |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05219994 -
Targeting the Carotid Bodies to Reduce Disease Risk Along the Diabetes Continuum
|
N/A | |
| Completed |
NCT04056208 -
Pistachios Blood Sugar Control, Heart and Gut Health
|
Phase 2 | |
| Completed |
NCT02284893 -
Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone
|
Phase 3 | |
| Completed |
NCT04274660 -
Evaluation of Diabetes and WELLbeing Programme
|
N/A | |
| Active, not recruiting |
NCT05887817 -
Effects of Finerenone on Vascular Stiffness and Cardiorenal Biomarkers in T2D and CKD (FIVE-STAR)
|
Phase 4 | |
| Active, not recruiting |
NCT05566847 -
Overcoming Therapeutic Inertia Among Adults Recently Diagnosed With Type 2 Diabetes
|
N/A | |
| Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
| Completed |
NCT04965506 -
A Study of IBI362 in Chinese Patients With Type 2 Diabetes
|
Phase 2 | |
| Recruiting |
NCT06115265 -
Ketogenic Diet and Diabetes Demonstration Project
|
N/A | |
| Active, not recruiting |
NCT03982381 -
SGLT2 Inhibitor or Metformin as Standard Treatment of Early Stage Type 2 Diabetes
|
Phase 4 | |
| Completed |
NCT04971317 -
The Influence of Simple, Low-Cost Chemistry Intervention Videos: A Randomized Trial of Children's Preferences for Sugar-Sweetened Beverages
|
N/A | |
| Completed |
NCT04496154 -
Omega-3 to Reduce Diabetes Risk in Subjects With High Number of Particles That Carry "Bad Cholesterol" in the Blood
|
N/A | |
| Completed |
NCT04023539 -
Effect of Cinnamomum Zeylanicum on Glycemic Levels of Adult Patients With Type 2 Diabetes
|
N/A | |
| Recruiting |
NCT05572814 -
Transform: Teaching, Technology, and Teams
|
N/A | |
| Enrolling by invitation |
NCT05530356 -
Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study
|
||
| Completed |
NCT04097600 -
A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (D) Semaglutide Tablets
|
Phase 1 | |
| Completed |
NCT03960424 -
Diabetes Management Program for Hispanic/Latino
|
N/A | |
| Completed |
NCT05378282 -
Identification of Diabetic Nephropathy Biomarkers Through Transcriptomics
|
||
| Active, not recruiting |
NCT06010004 -
A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes
|
Phase 3 | |
| Completed |
NCT03653091 -
Safety & Effectiveness of Duodenal Mucosal Resurfacing (DMR) Using the Revita™ System in Treatment of Type 2 Diabetes
|
N/A |